贝伐单抗联合培美曲塞加顺铂化疗方案对非小细胞肺癌患者生存率的影响

目的 分析贝伐单抗联合培美曲塞加顺铂化疗方案对非小细胞肺癌患者生存率的影响.方法 将我院收治的42例非小细胞肺癌患者随机分为观察组和对照组各21例,观察组患者采用贝伐单抗联合培美曲塞加顺铂化疗方案,对照组患者给予培美曲塞加顺铂化疗方案,21天为1个周期,观察比较两组患者2个周期以上的的近期疗效、远期疗效以及不良反应.结果 观察组客观有效率(ORR)为52.38%,显著高于对照组的28.57%,观察组的疾病控制率(DCR)为71.42%,显著高于对照组的61.9%,两组比较差异有统计学意义;观察组1年、3年和5年的生存率均明显高于对照组,差异有统计学意义;观察组的无进展生存时间(pFS)和总生存时间(OS)均显著优于对照组,两组比较差异有统计学意义;两组的不良反应主要表现在骨髓抑制和胃肠道反应方面,具体表现在血小板减少、贫血、白细胞减少、恶心呕吐、高血压、蛋白尿和鼻出血、咳血等方面,及时给予对症治疗后患者能够继续接受化疗.两组不良反应比较,差异无统计学意义.结论 贝伐单抗联合培美曲塞加顺铂化疗方案对非小细胞肺癌患者的治疗,与培美曲塞加顺铂化疗方案相比,疗效更加显著,患者的生存时间和生存率更高,没有加重患者的不良反应,患者的耐受性比较好,值得临床推广使用.

Impact of Bevacizumab Pemetrexed and Cisplatin Chemotherapy on Survival of Patients with Non-small Cell Lung Cancer

Objective To analyze the impact of bevacizumab pemetrexed and cisplatin chemotherapy on survival of pa -tients with non-small cell lung cancer .Methods 42 patients with non-small cell lung cancer were randomly divided into the con-trol group and the observation group ,each with 21 cases.The observation group received bevacizumab ,pemetrexed and cisplantin chemotherapy scheme ,and the control group received pemetrexed and cisplantin chemotherapy scheme ,21days was a cycle ,for 2 cycles.Short-term curative effect,long-term curative effect and adverse effects were observed and compared for above 42 days.Re-sults ORR of the observation group (52.38%) was significantly higher than the control group (28.57%),and DCR of the ob-servation group(71.42%) was significantly higher than the control group (61.9%),P<0.05,there had statistical difference;1-, 3-and 5-year survival rates of the observation group were significantly higher than those of the control group ,P<0.05,there had statistical difference.pFS and OS of the observation group was significantly higher than the control group ,P<0.05,there had sta-tistical difference;The adverse effects of the 2 groups were myelosuppression ,gastrointestinal reaction ,platelet,anemia,leukocyte, hypertensive,proteinuria,epistaixs,hemoptysis and so on,patients can continue to receive the chemotherapy after symptomatic treatment.There had no statistical difference in adverse effects ,P>0.05.Conclusion Bevacizumab,pemetrexed and cisplantin chemotherapy scheme is superior to the pemetrexed and cisplantin chemotherapy scheme for non -small cell lung cancer .The effect of the bevacizumab ,pemetrexed and cisplantin chemotherapy scheme is better ,and the survival rate and survival time are higher , without increase adverse effects and patients has a good tolerance .It is worthy of clinical application .